Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Athersys Inc (ATHX)

Athersys Inc (ATHX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Athersys to Participate in Three Upcoming Conferences Business Wire - Mon May 8, 2023

Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announced today its participation in three upcoming conferences...

ATHX : 0.0135 (-33.50%)
Athersys to Participate in The Cellular Therapies and Transfusion Medicine in Trauma and Critical Care Conference Business Wire - Mon May 1, 2023

Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announced today their participation in the Cellular Therapeutics...

ATHX : 0.0135 (-33.50%)
Athersys to Participate in The American Society for Neural Therapy and Repair Annual Conference Business Wire - Fri Apr 21, 2023

Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announced today their participation in The American Society...

ATHX : 0.0135 (-33.50%)
Athersys, Inc. Announces Closing of $3.7 Million Registered Direct Offering and Concurrent Private Placement Business Wire - Wed Apr 19, 2023

Athersys, Inc. (Nasdaq: ATHX) today announced that it has closed its previously announced offering to sell 3,685,000 shares (the “Shares”) of the Company’s common stock (or common stock equivalents...

ATHX : 0.0135 (-33.50%)
Athersys, Inc. Announces $3.7 Million Registered Direct Offering and Concurrent Private Placement Business Wire - Tue Apr 18, 2023

Athersys, Inc. (Nasdaq: ATHX) today announced that it has entered into definitive agreements for the purchase and sale of 3,685,000 shares (the “Shares”) of the Company’s common stock (or common...

ATHX : 0.0135 (-33.50%)
Athersys to Host Business Update Conference Call on April 20th Business Wire - Mon Apr 10, 2023

Athersys, Inc. (NASDAQ: ATHX) , a cell therapy and regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announced today it will host a business update conference...

ATHX : 0.0135 (-33.50%)
Athersys Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights Business Wire - Fri Mar 31, 2023

Athersys, Inc. (NASDAQ: ATHX) today announced financial results for the three and 12 months ended December 31, 2022, and provided a business update.

ATHX : 0.0135 (-33.50%)
Athersys Announces Successful Type B Meeting with the FDA Business Wire - Wed Mar 22, 2023

Athersys, Inc. (NASDAQ: ATHX) , a cell therapy and regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announced planned amendments to its MASTERS-2 clinical...

ATHX : 0.0135 (-33.50%)
Athersys Expands IP Protection with First New Patent for SIFU® Technology Business Wire - Tue Feb 28, 2023

Athersys, Inc. (NASDAQ: ATHX) , a cell therapy and regenerative medicine company developing MultiStem ® ( invimestrocel ) for critical care indications, announced today that the United States Patent...

ATHX : 0.0135 (-33.50%)
Athersys Granted Clinical Type B Meeting with FDA for MASTERS-2 Clinical Trial Protocol Discussion Business Wire - Tue Feb 14, 2023

Athersys, Inc. (NASDAQ: ATHX) , a cell therapy and regenerative medicine company developing MultiStem ® ( invimestrocel ) for critical care indications, announced today that the Company has been granted...

ATHX : 0.0135 (-33.50%)

Barchart Exclusives

1 EV Stock Under $10 With 25% Upside Potential Barchart - 1 hour ago
This charging stock has been under heavy pressure lately amid concerns over the fate of EV tax credits. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot